What Are Radiopharmaceuticals and How Are They Used in MBC?
Radiopharmaceuticals are drugs attached to radioactive molecules. Click here to learn about their safety and how they are being studied in clinical trials to help diagnose and treat MBC.
Dato-DXd Antibody-Drug Conjugate for Triple-Negative and Hormone Receptor-Positive MBC
Learn about how ADCs work and for research news about Dato-DXd.
ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Read for information on the FDA’s expanded approval of Trodelvy® and ASCO’s updated guidance on the use of this drug.
FDA Approves Orserdu and Expands Approval of Trodelvy®
Read about the clinical trials that contributed to 2 recent approvals of MBC treatment options.
New ESR1 Biomarker Research Leads to FDA Approval for ER+, HER2- MBC with an ESR1 Mutation
Click to learn about elacestrant (Orserdu) as well as the Guardant360 blood test that identifies people likely to benefit from the drug.
The Latest Research on CDK 4/6 Inhibitors
Learn about new CDK 4/6 inhibitor research in different breast cancer subtypes, including HER2+ and triple-negative MBC.
Why Knowing Your HER2 Status is Important
Did you know your HER2 status may change over time? Knowing your HER2 status is important to select the best MBC treatment. Learn more here.
Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2
Click to learn about biomarkers and targeted therapies for triple-negative MBC.
Why Does The Same Drug Work Differently In Different People?
Pharmacogenomics helps explain how your genes affect your body’s response to MBC treatment. Read more about how it is being studied in MBC clinical research.
Bispecific Antibodies: An Emerging Class Of MBC Drugs
Learn about bispecific antibodies, which bind to two targets instead of one, for MBC treatment.